Regeneron immunotherapy combo comes up short in melanoma trial
BioPharma Dive
A two-drug regimen of Regeneron s fianlimab and Libtayo didn t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market v
pharminent
May 18, 2026 (Last updated: May 18, 2026)
BioPharma Dive
A two-drug regimen of Regeneron s fianlimab and Libtayo didn t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market v